Related Experiment Video

Updated: Jun 6, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia

Dan-Dan Feng1, Hua Zhang, Peng Zhang

  • 1Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory for Biocontrol, Sun Yat-sen University, Guangzhou, China.

Journal of Cellular and Molecular Medicine
|November 13, 2010
PubMed

Insights

MicroRNAs miR-331-5p and miR-27a are downregulated in drug-resistant leukemia. Restoring these microRNAs increases sensitivity to chemotherapy, offering a potential therapeutic strategy for overcoming multidrug resistance (MDR) and preventing relapse.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Multidrug resistance (MDR) and disease relapse pose significant challenges in leukemia treatment.
  • Relapsed leukemia often becomes refractory to chemotherapy, necessitating a deeper understanding of resistance mechanisms.

Purpose of the Study:

  • To investigate the role of microRNAs (miRNAs) in the development of doxorubicin (DOX) resistance in leukemia cell lines.
  • To identify specific miRNAs that correlate with drug resistance and P-glycoprotein (P-gp) expression.

Main Methods:

  • Utilized miRNA microarray and quantitative real-time PCR (qRT-PCR) to analyze miRNA expression in leukemia cell lines with varying DOX resistance.
  • Employed miRNA transfection in DOX-resistant leukemia cells to assess the impact on drug sensitivity.

Main Results:

  • miR-331-5p and miR-27a expression showed an inverse correlation with P-glycoprotein (P-gp) expression in resistant leukemia cells.
  • Transfection with miR-331-5p and miR-27a restored sensitivity to DOX in resistant leukemia cell lines.
  • Lower levels of miR-331-5p and miR-27a were observed in relapsed leukemia patients compared to primary diagnosed patients.

Conclusions:

  • The expression of miR-331-5p and miR-27a is linked to the development of P-gp-mediated drug resistance in leukemia.
  • Restoring altered miRNA expression presents a potential therapeutic strategy to overcome leukemia drug resistance and prevent relapse.
  • Deregulation of miR-331-5p and miR-27a may contribute to leukemia relapse.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...